Expanding Market Presence Tilak Healthcare has successfully launched its flagship app OdySight in multiple countries including France, Spain, Belgium, and the US, indicating a strong international footprint and potential for expansion into additional markets with high ophthalmological needs.

Strong Investor Support Recent funding rounds totaling over 11 million USD, led by notable investors such as Elaia and Cap Horn, demonstrate robust investor confidence and provide resources for growth, product development, and sales efforts targeting healthcare providers and institutions.

Strategic Partnerships Partnerships with industry leaders like Novartis for medication monitoring and rehabilitation programs highlight opportunities to leverage these relationships for co-selling, joint marketing, and expanding into new therapeutic areas within ophthalmology.

Innovative Digital Approach Combining medical expertise with gaming and user engagement strategies positions Tilak as an attractive partner for healthcare providers seeking innovative, patient-friendly solutions for chronic eye condition management, opening avenues for direct sales to clinics, hospitals, and health systems.

Clinical and Reimbursement Potential OdySight's status as a CE-marked medical device supported by national healthcare systems suggests favorable reimbursement prospects and clinical adoption, making it easier to target healthcare professionals and institutions as potential clients or distribution partners.